Anders Hallberg increased its stake in Anika Therapeutics Inc (NASDAQ:ANIK) by 29.46% based on its latest 2016Q2 regulatory filing with the SEC. Healthinvest Partners Ab bought 111,586 shares as the company’s stock rose 17.44% with the market. The hedge fund run by Anders Hallberg held 490,331 shares of the medical and dental instruments company at the end of 2016Q2, valued at $21.93M, up from 378,745 at the end of the previous reported quarter. Healthinvest Partners Ab who had been investing in Anika Therapeutics Inc for a number of months, seems to be bullish on the $712.85M market cap company. The stock decreased 0.72% or $0.34 during the last trading session, hitting $46.89. About 101,701 shares traded hands. Anika Therapeutics Inc (NASDAQ:ANIK) has risen 27.86% since February 8, 2016 and is uptrending. It has outperformed by 11.37% the S&P500.
The institutional sentiment decreased to 0.81 in Q2 2016. Its down 0.46, from 1.27 in 2016Q1. The ratio is negative, as 16 funds sold all ANIK shares owned while 57 reduced positions. 11 funds bought stakes while 48 increased positions. They now own 11.10 million shares or 8.05% less from 12.07 million shares in 2016Q1.
Turner Investments L.P. holds 0.76% of its portfolio in ANIK for 45,000 shares. Diker Management Llc owns 33,965 shares or 0.71% of their US portfolio. Moreover, Thompson Siegel & Walmsley Llc has 0.51% invested in the company for 600,531 shares. The Massachusetts-based Btim Corp. has invested 0.45% in the stock. Portolan Capital Management Llc, a Massachusetts-based fund reported 51,540 shares.
Out of 2 analysts covering Anika Therapeutics (NASDAQ:ANIK), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Anika Therapeutics has been the topic of 3 analyst reports since October 12, 2015 according to StockzIntelligence Inc. Northland Capital downgraded the stock on April 27 to “Market Perform” rating.
Anika Therapeutics, Inc. is an orthopedic medicines company. The company has a market cap of $712.85 million. The Firm offers therapeutic pain management solutions. It has a 20.5 P/E ratio. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.